Clinical Trial Update: HBPL Study of the Impact of the NK1 Antagonist Aprepitant [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing the NK1 antagonist aprepitant for cocaine and alcohol dependence has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alcohol Dependence
• Cocaine Dependence

Drugs mentioned

• Aprepitant (aprepitant)

Snippet

Sponsor: University of Pennsylvania | Conditions: Cocaine Dependence, Alcohol Dependence | Phase 2 | Status: COMPLETED | Results posted: 2020-07-15